In the context of liver cancer, artemisinin has been demonstrated to reduce the protein expression of actin filament associated protein 1-like 2 (AFAP1L2) and reverses sorafenib resistance in specific liver cancer cell lines (Hep G2, Hep3B, MHCC-97 H, and Huh-7) [118]. Here, AFAP1L2 is linked to liver cancer.